Welcome to our dedicated page for GSRFR news (Ticker: GSRFR), a resource for investors and traders seeking the latest updates and insights on GSRFR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GSRFR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GSRFR's position in the market.
GSR IV Acquisition Corp. (NASDAQ: GSRF) has announced the pricing of its initial public offering, offering 20 million units at $10.00 per unit, targeting aggregate gross proceeds of $200 million.
Each unit comprises one Class A ordinary share and one-seventh of one right, with whole rights enabling holders to receive one Class A ordinary share upon business combination completion. Trading begins September 4, 2025, under symbol "GSRFU" on Nasdaq, with separate trading of shares and rights under "GSRF" and "GSRFR" respectively.
The company granted underwriters a 45-day option to purchase up to 3 million additional units. Polaris Advisory Partners and The Benchmark Company are serving as joint bookrunners, with Benchmark acting as Qualified Independent Underwriter.
